

SKYHAWK SKY-0515 UPDATE

Jan. 27, 2026 – Skyhawk Therapeutics Inc. announced encouraging interim results concerning SKY-0515, an investigational medicine being studied for Huntington disease (HD). These results are from the Phase 1 trial. There are not currently any Canadian study sites. The next step is the Phase 2/3 FALCON-HD study, which is currently enrolling participants in Australia, New Zealand, and Georgia. Other countries will be added soon.

RESOURCES

To read Skyhawk's community letter, [click here](#).

To read Skyhawk's press release, [click here](#).

More details are available at [ClinicalTrials.gov](https://clinicaltrials.gov) and www.FALCON-HD.com.

If you would like to connect with a member of the Family Services team, please reach out to your RCD or, if you're new to HSC, please fill out our online form: <https://contactme.cloud/form/huntingtonsociety>

STAYING CONNECTED

Staying connected with HSC is the best way to make sure you hear about new research opportunities and updates. You can also follow HSC on our social media: [Facebook](#), [Instagram](#), and [LinkedIn](#).